Investing
Acquired in-process research and development
AbbVie Acquired in-process research and development decreased by 52.8% to $1.27B in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 19.6%, from $1.57B to $1.27B. Over 4 years (FY 2021 to FY 2025), Acquired in-process research and development shows an upward trend with a 32.6% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementCash Flow Statement
SectionInvesting
CategoryGrowth
SignalHigher is better
VolatilityVolatile
First reportedQ1 2013
Last reportedQ4 2025
How to read this metric
High spending indicates a strong commitment to pipeline growth, though it carries significant execution and regulatory risk.
Detailed definition
Acquired In-Process Research and Development (IPR&D) represents the cash paid to acquire research projects that have not...
Peer comparison
A hallmark metric for pharmaceutical and biotech firms relying on external innovation.
Metric ID:
cf_acquired_ipr_dHistorical Data
19 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $132.00M | $402.00M | $905.00M | $145.00M | $269.00M | $40.00M | $243.00M | $150.00M | $280.00M | $66.00M | $282.00M | $164.00M | $937.00M | $82.00M | $1.57B | $248.00M | $823.00M | $2.68B | $1.27B |
| QoQ Change | — | +204.5% | +125.1% | -84.0% | +85.5% | -85.1% | +507.5% | -38.3% | +86.7% | -76.4% | +327.3% | -41.8% | +471.3% | -91.2% | >999% | -84.2% | +231.9% | +225.6% | -52.8% |
| YoY Change | — | — | — | — | +103.8% | -90.0% | -73.1% | +3.4% | +4.1% | +65.0% | +16.0% | +9.3% | +234.6% | +24.2% | +458.2% | +51.2% | -12.2% | >999% | -19.6% |
Range$40.00M – $2.68B
CAGR+65.2%
Avg YoY Growth+262.9%
Median YoY Growth+16.0%
Acquired in-process research and development at Other Companies
Frequently Asked Questions
- What is AbbVie's acquired in-process research and development?
- AbbVie (ABBV) reported acquired in-process research and development of $1.27B in Q4 2025.
- How has AbbVie's acquired in-process research and development changed year-over-year?
- AbbVie's acquired in-process research and development decreased by 19.6% year-over-year, from $1.57B to $1.27B.
- What is the long-term trend for AbbVie's acquired in-process research and development?
- Over 4 years (2021 to 2025), AbbVie's acquired in-process research and development has grown at a 32.6% compound annual growth rate (CAGR), from $1.62B to $5.02B.
- What does acquired in-process research and development mean?
- Cash spent to buy research and development projects from other companies.